Shasun Pharma Peer Comparison

NSE: SHASUNPHAR | BSE: 524552

₹428.55

₹21.95 (5.40%)

As on 17-Nov-2015IST

Market cap

₹2,884 Cr

Revenue (TTM)

₹1,074 Cr

P/E Ratio

63.8

P/B Ratio

Div. Yield

0 %

Edit

	Shasun Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	2,884	30,606	30,088	28,551	25,816
Revenue (₹ Cr)	1,074	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	44.72	414.00	288.22	-371.81	387.35
Net Margin (%)	4.11	11.23	14.79	-3.93	26.01
RoE (%)	10.33	8.38	29.77	-3.85	25.18
Price to Earnings	63.83	74.83	104.39	--	66.84
Price-To-Book	5.99	6.08	22.41	3.57	14.93

Income Statement (₹ Cr)

	Shasun Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	1,316.63	4,481.54	39.21	--	111.75
Total Income	1,328.86	4,548.09	39.54	--	111.77
Total Expenditure	1,196.75	3,772.14	28.05	--	103.45
EBITDA	119.87	709.40	11.16	--	8.29
Depreciation	46.96	145.40	5.18	--	0.72
EBIT	72.91	564.00	5.98	--	7.58
Interest	62.82	55.21	2.37	--	1.59
Other Income	12.23	66.55	0.33	--	0.02
Exceptional Items	7.85	49.83	--	--	--
Profit before Tax	30.17	575.34	3.94	--	6.01
Provision for Tax	6.33	162.65	1.27	--	1.91
Profit after Tax	23.84	412.69	2.67	--	4.10

	Shasun Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	378.74	3,715.35	47.49	--	14.83
Minority Interest	--	143.95	--	--	--
Non-Current Liabilities	182.64	1,872.46	11.98	--	6.27
Current Liabilities	908.61	1,772.97	24.42	--	37.80
Total Liabilities	1,482.25	7,504.73	83.90	--	59.21

	Shasun Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	683.88	3,983.17	53.02	--	11.26
Current Assets	784.37	3,521.56	30.88	--	47.65
Total Assets	1,482.25	7,504.73	83.90	--	59.21
Total Debt*	739.46	2,010.07	26.03	--	22.92
Net Current Assets	-124.24	1,748.59	6.46	--	9.84
Contingent Liabilities	187.61	295.45	4.70	--	--

	Shasun Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	84.18	354.96	10.55	--	-3.88
Cash Flow from Investing Activities	-144.63	-206.63	-5.46	--	-4.44
Cash from Financing Activities	50.97	-75.65	-10.21	--	8.61
Net Cash Inflow / Outflow	-9.48	72.68	0.34	--	0.29

	Shasun Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	8.82	11.25	9.04	--	25.03
ROE (%)	7.25	12.49	9.82	--	31.99
ROA (%)	1.71	5.84	3.33	--	8.42
EBIT Margin (%)	10.03	17.31	29.29	--	7.44
Net Margin (%)	1.79	9.07	6.75	--	3.66
Cash Profit Margin (%)	5.24	12.43	19.93	--	4.31

	Shasun Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	8.57	-7.22	-5.70	--	46.82
EBIT Growth (%)	0.02	-27.08	-2.08	--	24.42
Net Profit Growth (%)	-21.17	-51.03	-40.70	--	42.98
EPS Growth (%)	-25.95	-42.48	-40.70	--	42.98
Book Value Growth (%)	18.82	4.11	10.33	--	37.67

	Shasun Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	93.92	46.73	0.00	--	0.00
Price / Book Value	6.25	6.09	0.00	--	0.00
Dividend Yield (%)	0.00	1.07	--	--	--
EV/EBITDA	22.46	27.84	4.00	--	2.87
Market Cap (₹ Cr)	2,230.94	20,529.92	0.00	--	0.00

	Shasun Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	2.07	0.55	0.55	--	1.55
Short term debt to equity ratio	1.24	0.09	0.27	--	0.97
Current Ratio	0.86	1.99	1.26	--	1.26
Quick Ratio	0.60	1.41	1.22	--	0.89
Interest Coverage	1.48	11.42	2.66	--	4.78

	Shasun Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	26.40	16.54	42.87	--	21.80
Asset Turnover	0.97	0.64	0.49	--	2.30
Receivable days	94.19	49.71	143.12	--	61.92
Inventory Days	59.78	81.88	10.03	--	41.26
Payable days	85.59	136.23	216.06	--	94.00
Cash Conversion Cycle	68.38	-4.64	-62.91	--	9.17

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.